Table of Contents
EAST WINDSOR, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application prazosin hydrochloride capsules USP, 1mg, 2mg and 5mg. Aurobindo Pharma’s prazosin hydrochloride capsules, are an AB-rated generic equivalent to the reference listed drug (RLD), Minipress Capsules manufactured by Pfizer Inc.
Prazosin hydrochloride capsules are indicated for the treatment of hypertension, to lower blood pressure.
Prazosin hydrochloride capsules has an estimated market size of US $46.8 Million for the twelve months ending February 2023, as per IQVIA.
